Trials / Completed
CompletedNCT00037544
Study Evaluating ReFacto AF in Severe Hemophilia A
An Open-Label Study to Characterize the Safety and Efficacy of BDDrFVIII Manufactured by the Albumin Free Process (ReFacto AF) in the Treatment of Previously Treated Patients (PTP) With Severe Hemophilia A
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
To characterize the safety and efficacy of ReFacto AF in treating acute bleeding episodes during prophylaxis treatment, including neoantigenicity.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ReFacto AF |
Timeline
- Primary completion
- 2004-08-01
- Completion
- 2004-08-01
- First posted
- 2002-05-20
- Last updated
- 2008-04-22
Source: ClinicalTrials.gov record NCT00037544. Inclusion in this directory is not an endorsement.